References:

  1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.
  2. van der Heijde D, Kivitz A, Schiff MH, et al; for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):‍2136-2146.
  3. van der Heijde D, Salonen D, Weissman BN, et al; for the Canadian (M03-606) study group and the ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127.
  4. van der Heijde DM, Revicki DA, Gooch KL, et al; for the ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009;11(4):R124.
  5. Davis JC Jr, Revicki D, van der Heijde DMF, et al. Health‐related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007;57(6):1050-1057.
  6. Data on file, AbbVie Inc. ABVRRTI69264.
  7. Data on file, AbbVie Inc. ABVRRTI70163.
  8. Data on file, AbbVie Inc. ABVRRTI70582.
  9. Data on file, AbbVie Inc. ABVRRTI69846.
  10. Data on file, AbbVie Inc. ABVRRTI62920.